Search PubMed⌕ Search

Biomedical subjects

B Coiffier

Publications and source records attributed to B Coiffier.

At least 253 records · Page 14Linked to original sources
PubMed1980

Dihomogammalinolenic acid (20:3 omega 6) is more anti-aggregatory than eicosapentaenoic (20:5 omega 3) in a platelet-endothelial cell mixture.

The effect of 20:3 omega 6, the precursor of 1 series prostaglandins was to inhibit platelet aggregation more strongly than either 20:5 omega 3, the precursor of 3 series prostaglandins or 20:3 omega 3 which is not a substrate of prostaglandin synthetase. When platelets and dissociated endothelial cells were pretreated with 20:3 omega 6, platelet aggregation in the presence of endothelial cells was much more inhibited than after 20:5 omega 3 pretreatment.

8,11,14-Eicosatrienoic Acid↗
PubMed1978

[Prolonged survival in 16 cases of acute myeloid leukemia [author's transl)].

16 our of 370 acute myeloid leukemias treated between 1964 and 1973 have been in long survival for more than three years. In the first period 1964-1971 the overall remission rate was 20% and 6 patients has a long survival. In the last two years of study, 10 out of 96 patients have more than three years of survival, the remission rate was over 50%. All the cases were slightly proliferative the first group did not recieve intensive chemotherapy and appear as spontaneous long remission, but in thelast patients intensive chemotherapy seems responsible for the good results.

Adult↗
PubMed1978

BCG therapy in acute non lymphoid leukaemias.

The survival of patients with acute non-lymphoid leukaemias (ANLL) receiving chemotherapy (32 patients) or chemotherapy plus BCG (31 patients) has been compared in a randomized trial which started in Nov 1974. Fresh BCG (Institut Pasteur, Paris) was administered by Heaf gun in the interval of chemotherapy cycles. The overall survival was better in the chemo-immunotherapy group (median duration of survival of 25 months compared to 16 months in the chemotherapy group). However, the first remission duration did not differ (median duration of the 15 and 12 months, respectively). Plateau survival curves were not obtained in either group. A second complete remission was obtained in 7 out of 12 patients with bone marrow relapses in the chemo-immunotherapy group, and only in 2 out of 15 in the chemotherapy group (P less than 0.05). BCG seemed more efficient in patients older than 40 years; no difference was observed according to sex.

Acute Disease↗
PubMed1978

Bone marrow colony-forming cells in acute drug-induced agranulocytosis.

The capacity to differentiate and form colonies in vitro by bone marrow granulocytic precursor cells and its evolution were studied in eight cases of drug-induced acute agranulocytosis. In three cases colonies and clusters count were normal or high. These cases were probably immunological agranulocytosis. In the five other cases this number was very low and returned to normal from three to thirteen days. These were probably cases of marrow suppression by the drug.

Acute Disease↗
PubMed1977

Polymorphonuclear function in acute myeloblastic leukemia.

A study of granulocyte functions in acute myeloblastic leukemia is reported. Functions were assessed by the ability of polymorphonuclear to migrate in Boyden's chamber, to ingest and kill staphylococcus aureus. Chemotaxis was grossly impaired. Cellular imparirment of phagocytosis and bactericidal capacity was observed in 5 and 9 patients. An inhibitor of phagocytosis and bactericidal capacity was observed in 9 and 4 patients. Results improved in complete remission.

Blood Bactericidal Activity↗
PubMedDate not supplied

Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial.

From 1981 to 1984 a randomized clinical trial was conducted to evaluate the role of doxorubicin in low grade malignancy non-Hodgkin's lymphoma (NHL). One hundred and thirteen patients were treated by an induction regimen including cyclophosphamide 400 mg/m2 day 1 and 8, vincristine 1.4 mg/m2 day 1 and 8, procarbazine 80 mg/m2 day 1 to 14, prednisone 60 mg/m2 day 1 to 5 (PCOP regimen) randomly associated to doxorubicin: 20 mg/m2 day 1 and 8 (PACOP regimen). Maintenance therapy consisted of 12 monthly courses of chlorambucil 10 mg/m2 for 5 days or association of cyclophosphamide 300 mg/m2 for 3 days, vincristine 1.4 mg/m2 day 1 and prednisone 60 mg/m2 for 5 days. Complete response (CR) was obtained in 51 patients (45 per cent), in 30 patients after induction regimen and in 21 patients after maintenance therapy, without difference according to regimens. Bone marrow involvement (p = 0.02) and number of involved nodal sites (p = 0.001) were found to influence probability of achieving CR. The median time to progression was estimated to 39 months without difference between regimens. Median overall survival is not reached with a median follow-up of 53 months. Multivariate regression analysis permits observation of negative influence on survival of three parameters: initial bone marrow involvement, age over 50 years and incomplete response to treatment. The initial adjunction of doxorubicin did not seem to influence the appearance of histologic progression.

Antineoplastic Combined Chemotherapy Protocols↗
PubMedDate not supplied

Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study.

A prospective phase II study was performed to evaluate efficacy and toxicity of continuous infusion ifosfamide plus etoposide combination in elderly patients (older than 70 years) with intermediate or high grade non Hodgkin's lymphoma. Chemotherapy was administered with mesna in order to avoid hemorrhagic cystitis. The 21 patients included were either unable to receive the usual front-line chemotherapy given in our institution or relapsing after or not responding to conventional chemotherapy. Only one out of 97 courses of chemotherapy was followed by serious complication consisting in non-lethal pneumonitis. Four out of seven previously untreated patients and five patients treated in first relapse achieved complete response (75 per cent). Out of nine refractory or previously multi-treated patients, only one achieved complete response. We conclude that combination of continuous infusion ifosfamide plus etoposide deserves to be evaluated on a larger scale so that the optimum doses and schedule may be defined.

Aged↗
PubMedDate not supplied

Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.

High-dose chemotherapy supported with autologous peripheral stem cell transplantation is now widely used in the treatment of lymphoma patients. The benefit of high-dose therapy has been clearly established after relapse in patients with an aggressive histological subtype who respond to salvage therapy. However, the use of such treatment also deserves further evaluation in the first line of therapy in patients with adverse prognostic factors. In follicular lymphoma, autologous transplantation seems able to induce long-term responses in selected clinical situations, but randomized studies are awaited to evaluate the potential benefit of this approach. In other lymphoma subtypes, the use of high-dose therapy remains experimental and should still be tested in clinical trials. Given the feasibility and the limited toxicity of autologous peripheral stem cell transplantation, the comparison of different therapeutic strategies (optimal timing, treatments modalities) will be facilitated and will allow us to assess the best ways of using this treatment in lymphoma patients.

Antineoplastic Combined Chemotherapy Protocols↗